1-4 of 4
Nicola Dobbs
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor

Susannah J. Stanway, Atul Purohit, L.W. Lawrence Woo, Saulat Sufi, David Vigushin, Rebecca Ward, Richard H. Wilson, Frank Z. Stanczyk, Nicola Dobbs, Elena Kulinskaya, Moira Elliott, Barry V.L. Potter, Michael J. Reed, R. Charles Coombes
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1585–1592.
https://doi.org/10.1158/1078-0432.CCR-05-1996
Published: 06 March 2006
View article titled, Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor
Open the PDF for Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor in another window
Journal Articles

Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma

David J. Propper, David Chao, Jeremy P. Braybrooke, Pru Bahl, Parames Thavasu, Frances Balkwill, Helen Turley, Nicola Dobbs, Kevin Gatter, Denis C. Talbot, Adrian L. Harris, Trivadi S. Ganesan
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 84–92.
Published: 01 January 2003
View article titled, Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma
Open the PDF for Low-Dose IFN-γ Induces Tumor MHC Expression in Metastatic Malignant Melanoma in another window
Journal Articles

Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy

Adrian L. Harris, Petra Reusch, Bernhard Barleon, Cheng Hang, Nicola Dobbs, Dieter Marme
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1992–1997.
Published: 01 July 2001
View article titled, Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy
Open the PDF for Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy in another window
Journal Articles

A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis

Jeremy P. Braybrooke, Kenneth J. O’Byrne, David J. Propper, Andrew Blann, Mark Saunders, Nicola Dobbs, Cheng Han, Jane Woodhull, Karen Mitchell, Jeremy Crew, Kenneth Smith, Ross Stephens, Trivadi S. Ganesan, Denis C. Talbot, Adrian L. Harris
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4697–4704.
Published: 01 December 2000
View article titled, A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis
Open the PDF for A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis in another window